Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This survey is conducted to investigate safety and efficacy under the post marketed drug
utilization on the patient with rheumatoid arthritis (only for patients with an inadequate
response to prior conventional therapy) at the time of switching regimen from 10 mg twice a
week administration to 25 mg once a week administration.